Welcome to our dedicated page for Quipt Home Medical SEC filings (Ticker: QIPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quipt Home Medical Corp. (QIPT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, with AI-powered tools to help interpret complex documents. Quipt is a British Columbia corporation whose common shares trade on The Nasdaq Capital Market and the Toronto Stock Exchange, and it files reports with the U.S. Securities and Exchange Commission in connection with its status as a reporting issuer.
Among the key filings for Quipt are its Form 10-K annual reports and Form 10-Q quarterly reports, which include audited or reviewed financial statements, management’s discussion and analysis, and details on its home medical equipment and in-home respiratory care business in the United States healthcare market. These filings expand on topics referenced in press releases, such as recurring revenue from equipment rentals and respiratory resupplies, non-GAAP measures like Adjusted EBITDA, and risk factors related to reimbursement, regulation, and acquisitions.
Quipt also files Form 8-K current reports to disclose material events. Recent examples include an August 11, 2025 Form 8-K furnishing a press release on fiscal third quarter 2025 results, an August 12, 2025 Form 8-K describing the Equity Purchase Agreement for a 60% interest in Hart Medical Equipment, and a July 7, 2025 Form 8-K discussing the acquisition of a Ballad Health-owned durable medical equipment provider. On December 15, 2025, Quipt filed a Form 8-K detailing its entry into an Arrangement Agreement under which entities affiliated with Kingswood Capital Management and Forager Capital Management will acquire all outstanding Quipt shares for US$3.65 per share in cash.
These filings explain that, if the arrangement is consummated, Quipt’s shares will be delisted from The Nasdaq Capital Market and the Toronto Stock Exchange, de-registered under the Securities Exchange Act of 1934, and Quipt will cease to be a reporting issuer under Canadian securities laws. Until that transaction closes, investors can use this page to review Quipt’s ongoing SEC disclosures, including 8-Ks related to financial results, acquisitions, joint ventures, and the planned going-private transaction.
Stock Titan’s interface surfaces real-time updates from EDGAR and applies AI-generated summaries to help users quickly understand the contents of lengthy filings, including the implications of transaction agreements, non-GAAP reconciliations, and other technical disclosures related to Quipt’s home medical equipment and respiratory care operations.
Quipt Home Medical Corp.’s Chief Financial Officer Hardik Mehta reported dispositions of his equity as the company was acquired for US$3.65 per common share under a plan of arrangement. All issued and outstanding shares, other than any properly dissenting shares, were transferred to the purchasers for cash.
The filing shows 60,000 stock options disposed to the issuer and 366,471 common shares disposed at US$3.65 per share, leaving zero direct holdings reported. An additional 884,199 common shares held by the SK Family Trust for the benefit of Mr. Mehta’s children were also disposed at US$3.65 per share; Mr. Mehta disclaims beneficial ownership of those securities.
Quipt Home Medical Corp. submitted a Form 25 notification to remove its Common Shares from listing and registration on the Nasdaq Stock Market LLC. Nasdaq certified it has reasonable grounds for the filing and the Exchange and the issuer each attested compliance with the cited rules under 17 CFR 240.12d2-2 and 17 CFR 240.12d-2(c).
The form lists the issuer's principal office at 1019 Town Drive, Wilder, Kentucky 41076 and provides a telephone number. The notification is signed on behalf of Nasdaq by Tara Petta, AVP.
Quipt Home Medical Corp. has been acquired and taken private. An affiliate of REM Aggregator, LLC, through 1567208 B.C. Ltd., bought all outstanding Quipt common shares for cash at US$3.65 per share under a court-approved plan of arrangement.
The transaction values the cash consideration for shares, options and RSUs at approximately $173 million. All options and restricted share units were cancelled in exchange for cash, subject to tax withholdings, with out-of-the-money options receiving no payment.
Quipt became an indirect wholly owned subsidiary of Parent, triggering a change of control. The company is delisting its shares from the Nasdaq Capital Market and Toronto Stock Exchange and plans to terminate its U.S. and Canadian reporting obligations. The board was reconstituted, with several directors and senior officers resigning and then some being reappointed under the new ownership structure.
Quipt Home Medical Corp. has received a final court order in British Columbia approving its previously announced plan of arrangement. Under this deal, affiliates of Kingswood Capital Management and Forager Capital Management will acquire all outstanding common shares for cash consideration of US$3.65 per share.
The transaction remains subject to customary closing conditions and is expected to close by March 16, 2026. After completion, Quipt’s shares are expected to be delisted from the Toronto Stock Exchange and the Nasdaq Capital Market, and the company is expected to cease being a reporting issuer in Canada and the United States.
Quipt Home Medical Corp. reported that its shareholders approved a special resolution for a plan of arrangement under British Columbia corporate law. Under this arrangement, affiliates of Kingswood Capital Management, L.P. and Forager Capital Management, LLC are to acquire all issued and outstanding common shares for cash consideration of US$3.65 per share.
At the special meeting, shareholders holding 29,672,136 shares, or about 66.93% of outstanding shares as of the record date, were represented. The arrangement resolution received support from 98.9% of votes cast overall and 98.7% of votes cast after excluding interested and related parties under MI 61-101. Quipt plans to seek a final court order on March 5, 2026, and completion of the transaction remains subject to court, stock exchange and regulatory approvals and other closing conditions.
Claret Asset Management Corporation filed an amended Schedule 13G reporting its beneficial ownership in Quipt Home Medical Corp. common shares. CAMC reports beneficially owning 3,225,309 common shares, representing 7.33% of the class as of December 31, 2025.
CAMC has sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive power. The ownership percentage is based on 44,027,472 common shares outstanding as of December 12, 2025, as reported by Quipt Home Medical. Other persons have rights to receive proceeds from sales of these securities.
Quipt Home Medical Corp. reported strong top-line growth but remained slightly unprofitable for the quarter ended December 31, 2025, while advancing a pending cash buyout. Revenue rose to $80,996,000 from $61,381,000, driven mainly by acquisitions completed in 2025 and modest organic growth.
Adjusted EBITDA increased to $17,812,000 from $13,997,000, reflecting better operating scale, even as higher acquisition-related expenses, stock-based compensation, and professional fees kept the quarter in a net loss of $(1,053,000), similar to last year’s $(1,084,000). Operating cash flow remained solid at $8,941,000.
The company also highlighted its Arrangement Agreement under which a purchaser will acquire all common shares for $3.65 per share in cash, subject to shareholder, regulatory, and court approvals. If completed, Quipt will be taken private and its shares will be delisted from Nasdaq and the Toronto Stock Exchange.
Quipt Home Medical Corp. has called a special shareholder meeting to approve an arrangement under which a Kingswood-affiliated buyer will acquire all outstanding Quipt shares for US$3.65 in cash per share.
The March 3, 2026 meeting will ask investors to pass a special resolution requiring at least two‑thirds of votes cast, plus a separate simple majority excluding certain related holders under MI 61‑101. If approved and court‑sanctioned, Quipt will go private, its shares will be delisted, and options and RSUs will be cashed out. A termination fee of $6.95 million may be payable in specified failure or superior‑proposal scenarios.
Quipt Home Medical Corp. filed an amended annual report to add detailed Part III information on directors, executive compensation, ownership, related-party dealings, and auditor fees. The company had 44,329,972 common shares outstanding as of January 23, 2026.
The filing describes a pending Arrangement under which Purchaser entities agreed to acquire all Quipt shares for US$3.65 per share, with key shareholders and directors committed to vote in favor. It outlines a four-member board, fully independent key committees, and a new 2024 Equity Incentive Plan covering up to 8,420,494 shares, with 2,903,753 shares granted in fiscal 2025.
For 2025, CEO Gregory Crawford received total compensation of $3,043,176, largely in share-based awards, while CFO Hardik Mehta received $1,473,957. The report details change-in-control retention and severance terms for senior executives, related-party facility leases totaling future payments of $3,807,159 as of 2025, and auditor fees of $890,183 for 2025.
Quipt Home Medical Corp. reports that the U.S. Hart-Scott-Rodino antitrust waiting period has expired for its planned acquisition, under which a purchaser will acquire all outstanding Quipt common shares for $3.65 per share in cash by way of a court-approved plan of arrangement in British Columbia. The expiration of the HSR waiting period removes a key U.S. antitrust condition but the transaction still depends on other customary closing conditions, including approval by Quipt shareholders. The company reminds investors that completion of the deal is uncertain and subject to risks, and directs securityholders to review the forthcoming definitive management information circular and proxy statement before voting.